RT期刊文章SR电子T1 FDA批准治疗视神经节Neuromyelitis谱系障碍临床实践:一项调查学术Neuroimmunologists摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP S2 OP S2 10.1212/01. wnl.0000903060.69682.6b VO 99 23补首页充2 A1杰西塔迦尔索恩A1罗伯特Sharkus A1理查德A1克里斯托猎人A1詹姆斯Siegler A1奥尔加索恩年2022 UL //www.ez-admanager.com/content/99/23_Supplement_2/S2.1.abstract AB客观评估利用率和使用障碍三个最近FDA批准的治疗视Neuromyelitis学术Neuroimmunologists谱系障碍(NMOSD)。背景自2019年以来,eculizumab、inebilizumab satralizumab收到FDA批准用于治疗aquaporin-4免疫球蛋白阳性(AQP4 +) NMOSD后显示效果在减少攻击频率。然而,所知甚少的采用这些治疗方法付诸实践或使用障碍。我们进行了一项调查学术neuroimmunologists识别当前的治疗实践。设计/方法neuroimmunologists电子调查研究的我们。接受者被确定在部门网站上的university-associated与附属医院神经病学派驻。首页这项调查是通过电子邮件管理,包括与临床相关的问题背景,病人组,治疗用在不同的场景中,障碍。作者对受访者的身份也不清楚。结果383 neuroimmunologists从105年机构确认,其中33从18个州完成了调查。几乎所有人(88%)报告新fda批准的治疗患者(非功能性测试)。没有报道不适与病人讨论任何非功能性测试。受访者表示非同寻常的临床稳定的病人转向非功能性测试(69%从来没有开关,开关1 22% - 25%的时间)。 For newly diagnosed AQP4+ NMOSD patients, NFT initiation rates varied (16% initiate none, 42% 1-25% of the time, 6.5% 25-50%, 19% 50-75%, 16% 75-100%). For patients with a relapse, responses were dichotomized regarding switching to NFTs - respondents either switch 75-100% of their patients (60%) or none or 1-25% (16%, 24% respectively). Nearly half (16/33) of respondents reported being unable to start NFTs, with insurance/cost issues being the most cited barrier.Conclusions Among academic neuroimmunologists, FDA-approved therapies for AQP4+ NMOSD are being utilized for newly diagnosed patients and those with disease recurrence, although individual practice patterns vary. The main perceived barriers to NFT use are insurance/cost-related issues.

map